Eli Rosenbaum

7.9k total citations
112 papers, 3.6k citations indexed

About

Eli Rosenbaum is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Eli Rosenbaum has authored 112 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Pulmonary and Respiratory Medicine, 37 papers in Oncology and 36 papers in Molecular Biology. Recurrent topics in Eli Rosenbaum's work include Prostate Cancer Treatment and Research (37 papers), Bladder and Urothelial Cancer Treatments (17 papers) and Radiopharmaceutical Chemistry and Applications (15 papers). Eli Rosenbaum is often cited by papers focused on Prostate Cancer Treatment and Research (37 papers), Bladder and Urothelial Cancer Treatments (17 papers) and Radiopharmaceutical Chemistry and Applications (15 papers). Eli Rosenbaum collaborates with scholars based in Israel, United States and Italy. Eli Rosenbaum's co-authors include David Sidransky, William H. Westra, Mohammad Obaidul Hoque, Yoram Cohen, Shahnaz Begum, Marianna Zahurak, Rui Henrique, Ralph P. Tufano, Wim Van Criekinge and Martha A. Zeiger and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and JNCI Journal of the National Cancer Institute.

In The Last Decade

Eli Rosenbaum

106 papers receiving 3.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eli Rosenbaum Israel	34	1.7k	1.0k	972	787	655	112	3.6k
Erich M. Sturgis United States	32	1.4k 0.8×	1.2k 1.2×	673 0.7×	436 0.6×	561 0.9×	80	3.3k
Andrea Haitel Austria	42	2.0k 1.2×	1.1k 1.0×	2.3k 2.4×	462 0.6×	849 1.3×	153	5.3k
Dario Giuffrida Italy	30	818 0.5×	1.0k 1.0×	475 0.5×	2.2k 2.8×	452 0.7×	94	3.6k
Atsuhiko Sakamoto Japan	28	618 0.4×	1.0k 1.0×	397 0.4×	1.1k 1.3×	277 0.4×	126	3.5k
Koichiro Akakura Japan	31	650 0.4×	569 0.6×	2.4k 2.4×	497 0.6×	388 0.6×	171	3.1k
William N. William United States	33	893 0.5×	2.0k 2.0×	1.5k 1.5×	173 0.2×	559 0.9×	109	4.0k
Liborio Torregrossa Italy	30	765 0.4×	762 0.7×	281 0.3×	2.2k 2.8×	326 0.5×	119	3.3k
Bernhard J. Eigl Canada	28	1.7k 1.0×	1.5k 1.5×	3.2k 3.3×	235 0.3×	1.6k 2.4×	135	4.6k
Sigurd Lax Austria	39	1.5k 0.9×	2.1k 2.1×	867 0.9×	175 0.2×	1.8k 2.8×	145	5.9k
Vincent Molinié France	33	1.9k 1.1×	609 0.6×	2.3k 2.4×	171 0.2×	949 1.4×	166	4.1k

Countries citing papers authored by Eli Rosenbaum

Since Specialization

Citations

This map shows the geographic impact of Eli Rosenbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eli Rosenbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eli Rosenbaum more than expected).

Fields of papers citing papers by Eli Rosenbaum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eli Rosenbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eli Rosenbaum. The network helps show where Eli Rosenbaum may publish in the future.

Co-authorship network of co-authors of Eli Rosenbaum

This figure shows the co-authorship network connecting the top 25 collaborators of Eli Rosenbaum. A scholar is included among the top collaborators of Eli Rosenbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eli Rosenbaum. Eli Rosenbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Koshkin, Vadim S., Pongwut Danchaivijitr, Woo Kyun Bae, et al.. (2024). Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy. European Urology. 87(4). 390–395. 1 indexed citations

Sharon, Yoray, et al.. (2024). Gold nanoparticles for safe delivery of cisplatin. 26–26.

Keizman, Daniel, Moshe Frenkel, Avivit Peer, et al.. (2023). Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study. Nutrients. 15(16). 3533–3533. 6 indexed citations

Sharon, Yoray, et al.. (2023). A ‘golden’ alternative for prevention of cisplatin nephrotoxicity in bladder cancer. Cancer Nanotechnology. 14(1). 2 indexed citations

Keizman, Daniel, Moshe Frenkel, Avivit Peer, et al.. (2023). P-MCP treatment in non-metastatic biochemically relapsed prostate cancer (BRPC-M0): Final long-term results of a prospective phase II study.. Journal of Clinical Oncology. 41(6_suppl). 162–162. 1 indexed citations

Koshkin, Vadim S., Pongwut Danchaivijitr, Woo Kyun Bae, et al.. (2023). 2378P Efficacy and safety outcomes with pembrolizumab (pembro) rechallenge for patients (pts) with advanced/metastatic urothelial cancer (UC) who responded to first-course treatment. Annals of Oncology. 34. S1211–S1211. 2 indexed citations

Ber, Yaara, Avivit Peer, Eli Rosenbaum, et al.. (2021). Cardiovascular Proteomics: A Post Hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist vs GnRH Agonist among Men with Advanced Prostate Cancer. The Journal of Urology. 206(4). 952–959. 5 indexed citations

Gillis, Roni, et al.. (2019). Increased Incidence of Lung Cancer Among Patients With Superficial Transitional Cell Carcinoma: A Potential Risk Cohort for Lung Cancer Screening. Clinical Lung Cancer. 20(6). 429–434. 1 indexed citations

Sartor, Oliver, Daniel Heinrich, Neil Mariados, et al.. (2017). Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. Annals of Oncology. 28(10). 2464–2471. 21 indexed citations

10.

Sarfaty, Michal, Moshe Leshno, Noa Gordon, et al.. (2017). Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. European Urology. 73(4). 628–634. 58 indexed citations

11.

Neiman, Victoria, Daniel Keizman, David Sarid, et al.. (2016). Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib. Annals of Oncology. 27. vi289–vi289.

12.

Sartor, Oliver, Daniel Heinrich, Neil Mariados, et al.. (2016). Radium-223 re-treatment from an international, prospective, open-label study in patients with castration-resistant prostate cancer and bone metastases. Annals of Oncology. 27. vi255–vi255. 1 indexed citations

13.

Grenader, Tal, et al.. (2012). Spontaneous Regression of Metastatic Papillary Renal Cell Cancer After Cessation of Treatment With Sorafenib. Clinical Genitourinary Cancer. 11(2). 201–203. 2 indexed citations

14.

Kovjazin, Riva, Ilan Volovitz, Yulia Kundel, et al.. (2011). ImMucin: A novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors. Vaccine. 29(29-30). 4676–4686. 34 indexed citations

15.

Brait, Mariana, Leonel Maldonado, Myriam Loyo, et al.. (2011). DNA methylation profiles delineate epigenetic heterogeneity in seminoma and non-seminoma. British Journal of Cancer. 106(2). 414–423. 48 indexed citations

16.

Hoque, Mohammad Obaidul, Myoung Sook Kim, Kimberly Laskie Ostrow, et al.. (2008). Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome. Cancer Research. 68(8). 2661–2670. 115 indexed citations

17.

Hu, Shuiying, Dingxie Liu, Ralph P. Tufano, et al.. (2006). Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. International Journal of Cancer. 119(10). 2322–2329. 157 indexed citations

18.

Hoque, Mohammad Obaidul, Shahnaz Begum, Özlem Topaloglu, et al.. (2006). Quantitation of Promoter Methylation of Multiple Genes in Urine DNA and Bladder Cancer Detection. JNCI Journal of the National Cancer Institute. 98(14). 996–1004. 212 indexed citations

19.

Hoque, Mohammad Obaidul, Eli Rosenbaum, William H. Westra, et al.. (2005). Quantitative Assessment of Promoter Methylation Profiles in Thyroid Neoplasms. The Journal of Clinical Endocrinology & Metabolism. 90(7). 4011–4018. 104 indexed citations

20.

Begum, Shahnaz, Eli Rosenbaum, Rui Henrique, et al.. (2004). BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Modern Pathology. 17(11). 1359–1363. 135 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact